Literature DB >> 29172941

Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios.

Daniel N A Ankrah1,2, Delese M Darko3, George Sabblah3, Aukje Mantel-Teeuwisse2, Hubert M G Leufkens2,4.   

Abstract

BACKGROUND: Timely reporting of safety information post vaccination is pivotal for the success of any vaccination program. Reports of adverse events following immunization (AEFI) of 6 different vaccinations from Ghana were analysed for signals.
METHODS: De-identified data from active surveillance for AEFIs after 2009 AH1N1 influenza, yellow fever, meningitis, measles-rubella, pneumococcal-rotavirus and human papilloma virus vaccinations were used. All vaccinations occurred between January 2010 and December 2013. The ten most occurring events for each vaccination were captured and arranged using Medical Dictionary for Regulatory Authorities (MedDRA) Preferred Term (PT) and System Organ Classification (SOC) codes. Adverse event incidence rates were calculated for each vaccine type, and signals were generated using proportional reporting ratios (PRR).
RESULTS: A total number of 5,141 reports were analysed ranging from 33 (human papilloma virus) to 1958 (measles-rubella). Between 22% and 55% of all AEFIs per vaccine type were collected on the day of vaccination. For each vaccine type, at least 87% of all reported AEFIs occurred in the first 7 days post-vaccination. Multiple reports were received per vaccine type. For the MR vaccine, urticarial recorded the highest attack rate of 6.6 (95% CI 6.2, 7.1) per 100,000 vaccines. The AEFI with the highest PRR for both human papilloma and measles-rubella vaccines was abdominal pain, recording a PRR of 8.15 (95% CI 3.46, 19.23) and 43.75 (95% CI 17.81, 107.45) respectively.
CONCLUSION: These results underscore the competency of public health systems in sub-Saharan African countries (like Ghana) to identify most frequently occurring and important vaccine related safety issues.

Entities:  

Keywords:  Ghana; active surveillance; immunization; proportional reporting ratio; safety

Mesh:

Year:  2017        PMID: 29172941      PMCID: PMC5791568          DOI: 10.1080/21645515.2017.1384105

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  25 in total

1.  The rotavirus vaccine story: a clinical investigator's view.

Authors:  M B Rennels
Journal:  Pediatrics       Date:  2000-07       Impact factor: 7.124

2.  Surveillance of adverse events following immunisation: Australia, 2000-2002.

Authors:  Glenda Lawrence; Robert Menzies; Margaret Burgess; Peter McIntyre; Nicholas Wood; Ian Boyd; Patrick Purcell; David Isaacs
Journal:  Commun Dis Intell Q Rep       Date:  2003

3.  Population-based active surveillance cohort studies for influenza: lessons from Peru.

Authors:  Hugo Razuri; Candice Romero; Yeny Tinoco; Maria Claudia Guezala; Ernesto Ortiz; Maria Silva; Erik Reaves; Maya Williams; Victor Alberto Laguna-Torres; Eric S Halsey; Jorge Gomez; Eduardo Azziz-Baumgartner; Marc-Alain Widdowson; Joe Bresee; Ann Moen; Timothy M Uyeki; Andrew Bennett; Joel M Montgomery; Daniel G Bausch
Journal:  Bull World Health Organ       Date:  2012-04-01       Impact factor: 9.408

4.  Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems.

Authors:  Jan Bonhoeffer; Adwoa Bentsi-Enchill; Robert T Chen; Margaret C Fisher; Michael S Gold; Katharina Hartman; Ulrich Heininger; Bernard Hoet; Thomas Jefferson; Najwa Khuri-Bulos; Katrin Kohl; S Michael Marcy; David Nalin; Robert Pless; Hernan Sanabria-Rojas; Karen Sleeman; Robert Wise
Journal:  Vaccine       Date:  2008-12-04       Impact factor: 3.641

5.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

6.  Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.

Authors:  Claude-Roger Ouandaogo; Téné M Yaméogo; Fabien V K Diomandé; Charles Sawadogo; Bassirou Ouédraogo; Rasmata Ouédraogo-Traoré; Lorenzo Pezzoli; Mamoudou H Djingarey; Nehémie Mbakuliyemo; Patrick L F Zuber
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

7.  Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study.

Authors:  Daniel N A Ankrah; Aukje K Mantel-Teeuwisse; Marie L De Bruin; Philip K Amoo; Charles N Ofei-Palm; Irene Agyepong; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

8.  [BCG vaccine coverage in private medical practice: First data in children below two years old, seven months after the end of compulsory vaccination in France].

Authors:  J-P Guthmann; F de La Rocque; M Boucherat; D van Cauteren; L Fonteneau; A Lécuyer; R Cohen; D Lévy-Bruhl
Journal:  Arch Pediatr       Date:  2009-03-21       Impact factor: 1.180

9.  High uptake of Gardasil vaccine among 9 - 12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa.

Authors:  I Moodley; N Tathiah; V Mubaiwa; L Denny
Journal:  S Afr Med J       Date:  2013-05

10.  Paediatric pharmacovigilance: use of pharmacovigilance data mining algorithms for signal detection in a safety dataset of a paediatric clinical study conducted in seven African countries.

Authors:  Dan K Kajungu; Annette Erhart; Ambrose Otau Talisuna; Quique Bassat; Corine Karema; Carolyn Nabasumba; Michael Nambozi; Halidou Tinto; Peter Kremsner; Martin Meremikwu; Umberto D'Alessandro; Niko Speybroeck
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

View more
  1 in total

1.  Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies.

Authors:  Jerome Ateudjieu; Beat Stoll; Anne Cecile Bisseck; Ayok M Tembei; Blaise Genton
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.